Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease

Compound Formula Rehmannia has been shown to be clinically effective in treating Parkinson's disease and levodopa-induced dyskinesia; however, the mechanisms remain unclear. In this study, we established a model of Parkinson's disease dyskinesia in rats, and treated these animals with Compound Formula Rehmannia. Compound Formula Rehmannia inhibited the increase in mRNA expression of N-methyl-D-aspartate receptor subunits 1 and 2 and excitatory amino acid neurotransmitter genes, and it inhibited the reduction in expression of γ-aminobutyric acid receptor B1, an inhibitory amino acid neurotransmitter gene, in the corpus striatum. In addition, Compound Formula Rehmannia alleviated dyskinesia symptoms in the Parkinson's disease rats. These experimental findings indicate that Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease by modulating neurotransmitter signaling in the corpus striatum.

• Publication year

  2014

• Venue

  Neural Regeneration Research

• Publication date

  2014-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.4103/1673-5374.128246PMID 25206828PMCID 4146199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EFFECTS OF DESTRUCTION OF SUBTHALAMIC NUCLEUS ON SPOTANEOUS DISCHARGE OF GLOBUS PALLIDUS NEURONS IN RATS

  2013cited by this paper
• Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease

  2012cited by this paper
• Dynamic changes of amino acid content in the LID model of Yin-deficiency and Wind-agitation in Parkinson's disease and intervening effects of the compound rehmannia formula

  2012influential reference
• Study on the traditional Chinese medicine syndrome properties of the rat models of Parkinson's disease and "combining syndrome and disease" induced by 6-hydroxydopamine

  2011influential reference
• Different Treatment Methods on Dynamic Changes of D_2 Receptors in Parkinson's Disease Rats in PD Rats

  2011cited by this paper
• Effects of different doses of levodopa on neuroethology of rats with Parkinson's disease

  2011cited by this paper
• The Literature Research of Syndromes of TCM about Parkinson's Disease

  2011cited by this paper
• Levodopa in Parkinson's disease: from the past to the future

  2010cited by this paper
• The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease

  2010cited by this paper
• The method of simultaneous measurement of the plasma concentration of L-DOPA and extracellular amino acids in striatum of the Parkinson's disease rats induced by 6-OHDA

  2010cited by this paper
• Levodopa‐induced dyskinesias

  2007cited by this paper
• NMDA receptor surface mobility depends on NR2A-2B subunits

  2006cited by this paper
• Clinical Observation on Treatment of Parkinson's Disease by Nourishing Liver and Kidney

  2006cited by this paper
• [The excitatory role of GABA during the early development of the central nervous system].

  2003cited by this paper
• Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model.

  2000cited by this paper
• Prospects of glutamate antagonists in the therapy of Parkinson's disease

  1998cited by this paper
• Basal ganglia pathophysiology. A critical review.

  1997cited by this paper
• Microelectrode recording-guided posteroventral pallidotomy in patients with Parkinson's disease.

  1997cited by this paper
• Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.

  1991cited by this paper
• Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

  1991cited by this paper
• 6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

  1968cited by this paper
• A stereotaxic atlas of the rat brain

  1967cited by this paper

• Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review

  2021cites this paper
• Current Knowledge on the Background, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesia – Literature Review.

  2021cites this paper
• Protective Effect of Compound Formula Rehmannia against Neurotoxicity and Apoptosis Induced by α-Syn in In Vivo and In Vitro Models of Parkinson's Disease

  2020cites this paper
• Dried Rehmannia root protects against glutamate-induced cytotoxity to PC12 cells through energy metabolism-related pathways

  2017cites this paper
• Palmitoyl Serotonin Inhibits L-dopa-induced Abnormal Involuntary Movements in the Mouse Parkinson Model

  2016cites this paper
• A novel method for evaluating brain function and microstructural changes in Parkinson's disease

  2015cites this paper
• An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response

  2015cites this paper